All News

Jo1.gottrons.jpg

FDA Approves IVIG in Dermatomyositis

d Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).

Read Article
infused.jpg

Canakinumab Fails to Improve COVID-19 Survival

d Jack Cush, MD

JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.

Read Article
artangiogca.jpg

ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis

d Jack Cush, MD

The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and surgical interventions. Recommendations for GCA and TAK include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of glucocorticoids as initial therapy.

Read Article
EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Links:

Dr. John Cush RheumNow ( View Tweet)

US life expectancy dropped by 1.5 years in 2020, driven by the pandemic. https://t.co/89i333vmPv

Links:

Dr. John Cush RheumNow ( View Tweet)

#VaccinationCovid DOES induce #SARS_CoV_2-specific #antibodies in #Rituximab-treated patients, after peripheral B-cells have at least partially repopulated! In addition, T cell responses (independent of B cell status) may also exert protective effects! https://t.co/E1FErHJtd3

Links:

Daniel Aletaha DanielAletaha ( View Tweet)

Canakinumab Fails to Improve COVID-19 Survival https://t.co/ngThAgfHTq JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival patients hospitalized with severe COVID-19. https://t.co/pUBmt85jAC

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 39 studies, 15,673 pts with nail psoriasis = 100% improvement of the Nail Psoriasis Severity Index, ixekizumab was best @ 24 wks (OR 2.98; 95% CI, 1.74-5.10), followed by TNF inhibitor (infliximab, adalimumab). https://t.co/VnhbMPYEV7

Links:

Dr. John Cush RheumNow ( View Tweet)

Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w10hs5

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA delays in the analysis of Pfizers/Xeljanz Oral Surveillance Safety study has put off potential approvals for other JAKs (Lillys Oluminant in Eczema & Abbvies Rinvoq for Eczema, Psoriatic arthritis, Ank Spondylitis). The wait continues.. https://t.co/3pRp2Vnuhw

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: 263 RA patients with ILD were treated w/ Abatacept (ABA mono, ABA+MTX or ABA+nonMTX) - all improved their DAS28, stabilized their FVC, DLCO, Chest CT; Only difference was that steroid sparing best when ABA used in combo. https://t.co/1dGufcsRpC

Links:

Dr. John Cush RheumNow ( View Tweet)

National Inpatient study (2000-2014) shows increased risk of vertebral compression fractures (VCF) in Ankylosing spondylitis (2.7%), compared to RA 0.77% & gen population 0.35%. VCF Hosp increased over time in AS, but decr in RA pts https://t.co/ugV44XJf8a

Links:

Dr. John Cush RheumNow ( View Tweet)

152 Israeli pts w/ Breakthrough COVID infx >7d after 2nd Pfizer vax; all hospitalized, 38 w/ Poor outcome & 22% (34/152) died. All were older, most males, w/ comorbidities, 40% immunocompromised; high risk w/ RTX & low anti-spike IgG titers https://t.co/x1Uuyo7qim

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 33 RCTs, 4544 pts Rx w/ either IL-17 or TNF inhibitors finds lower risk of UVEITIS with anti-TNF mAb (vs PBO OR = 0.46; vs IL-17i OR = 0.34. IL-17 inhibitors are not protective against uveitis https://t.co/AIxgI2qhq9

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 647 RA pts wanting to get pregnant finds only 3.9% SSA+ & 1.1% SSB+ (higher in RF+ pts); ~1/2 had SSA titre of >240 units/mL - but No cases of neonatal lupus or heart block seen. In a French register, SSA related CHB was 1.5% https://t.co/FmZzPpmB7D

Links:

Dr. John Cush RheumNow ( View Tweet)

Can you refuse to see unvaccinated pts? NY Times letter reviews options for “vaccine hesitant” or “vaccine refusing” 1. Ask if vaccinated 2. Offer telehealth 3. Require masks & distancing 4. Minimize contact betw vax & no-vax pts 5. Address pt concerns https://t.co/LEJLDMIDyF https://t.co/stoUpzzK02

Links:

Dr. John Cush RheumNow ( View Tweet)
Botanical extract, Chrysanthemum zawadskii var. latilobum (GCWB) studied in 112 w/ mild-mod. knee OA. Randomized, double-blind, placebo-controlled study finds GCQB signif better than placebo in WOMAC total & function scores https://t.co/xyKlrL2CG7

Links:

Dr. John Cush RheumNow ( View Tweet)

Sweets Syndrome (Acute Febrile Neutrophilic Dermatosis) in NEJM. A 46-year-old woman with erythematous painful raised lesions on her thumb, arms and other areas. https://t.co/Tggz1lLULR

Links:

Dr. John Cush RheumNow ( View Tweet)

Do Women or Men make the best doctors? https://t.co/HTtZd9GHRH+

Links:

Dr. John Cush RheumNow ( View Tweet)

Carpal Tunnel Syndrome has an annual incidence of 0.4%. Population based study shows more likely in women, 50-59 years, w/ obesity, gout, rheumatoid arthritis or a prior hx of wrist injury. https://t.co/X7U5yh0R3l

Links:

Dr. John Cush RheumNow ( View Tweet)

×